HISUN(SH:600267) Xin Lang Cai Jing·2025-09-19 03:21Group 1 - The core viewpoint of the news is that Zhejiang Hai Zheng Pharmaceutical Co., Ltd. has experienced fluctuations in its stock price and financial performance, with a notable decline in net profit despite a slight increase in revenue [1][2]. - As of September 19, the stock price of Hai Zheng Pharmaceutical fell by 2.05% to 10.52 CNY per share, with a total market capitalization of 12.612 billion CNY [1]. - The company has seen a year-to-date stock price increase of 29.96%, but it has declined by 1.13% in the last five trading days and 7.80% in the last 20 days [1]. Group 2 - Hai Zheng Pharmaceutical's main business segments include pharmaceutical manufacturing, with a revenue composition of 39.38% from pharmaceutical commerce, 18.26% from anti-infection drugs, and 13.01% from cardiovascular drugs [1]. - For the first half of 2025, the company reported a revenue of 5.250 billion CNY, reflecting a year-on-year growth of 0.13%, while the net profit attributable to shareholders decreased by 31.29% to 299 million CNY [2]. - The company has distributed a total of 1.726 billion CNY in dividends since its A-share listing, with 445 million CNY distributed in the last three years [3].